Short answer: if you have already had a heart attack, stroke, stent, bypass or peripheral artery disease, the evidence that a statin lowers your chance of another event is strong and consistent — this is not one of medicine's live controversies. If you have not, the picture is genuinely more nuanced: the proportional benefit looks similar in women and men, but the absolute benefit depends entirely on how high your risk is to begin with, and women were historically underrepresented in the trials. That is why guidelines frame it as a shared decision rather than an automatic prescription. Nothing here is a recommendation to start, stop or change a medication — that is your prescriber's call.
Why the answer is different before and after a cardiac event
Statins do the same biological thing in both situations: they lower LDL cholesterol and stabilise arterial plaque. What changes is the arithmetic. If your ten-year risk of a heart attack or stroke is 30%, cutting it by a fifth removes about six events per hundred women treated. If your risk is 3%, the same proportional cut removes about 0.6 events per hundred — real, but small enough that side effects, cost, and how you personally feel about daily medication reasonably enter the conversation.
The largest pooled analysis of individual patient data from 27 randomised trials (174,000 people, 46,675 of them women) found that each 1 mmol/L (about 39 mg/dL) reduction in LDL cholesterol cut major vascular events by roughly 16% in women (rate ratio 0.84) — closely comparable to the effect in men. The honest caveat: women were only 27% of participants, and they entered the trials at lower average risk, which is precisely why the female primary-prevention subgroups were smaller and less statistically decisive than anyone would like.
What do guidelines actually say for women without heart disease?
The US Preventive Services Task Force concluded with moderate certainty that adults aged 40–75 with no history of cardiovascular disease, at least one risk factor (abnormal cholesterol, diabetes, high blood pressure or smoking), and an estimated 10-year risk of 10% or greater get at least a moderate net benefit from a statin. Between 7.5% and under 10% risk, the wording drops to "selectively offer" — meaning discuss it, do not assume it. For adults 76 and older starting fresh, the USPSTF says the evidence is insufficient. That is not a euphemism for "no": it means nobody has run the trial that would settle it.
The 2026 ACC/AHA lipid guideline update moved risk estimation to the PREVENT equations, partly because the older Pooled Cohort Equations overestimated ten-year risk by an estimated 40–50%. Under PREVENT, risk is banded as low (<3%), borderline (3% to <5%), intermediate (5% to <10%) and high (≥10%). If you were told years ago that your risk was "borderline," it is worth knowing the number may have been generated by a calculator that has since been retired. You can explore the inputs with our heart risk check, and see how your numbers compare in cholesterol levels by age.
The women-specific risk factors that get missed
Guidelines list "risk-enhancing factors" that nudge an uncertain decision one way. Several are reproductive and routinely go unasked: menopause before age 40, premature ovarian insufficiency, a history of preeclampsia or gestational hypertension, gestational diabetes, and preterm delivery. Also on the list: chronic inflammatory conditions such as rheumatoid arthritis, psoriasis and lupus, which are more common in women. If your obstetric history is decades old and no clinician has ever asked about it, it is reasonable to raise it yourself. More on the underlying biology in menopause and heart health and high cholesterol in women.
| Your situation | What the evidence supports | Strength of evidence |
|---|---|---|
| Previous heart attack, stroke, stent, bypass or peripheral artery disease | Clear reduction in further events; guidelines recommend statin therapy unless there is a specific reason not to | Strong, consistent |
| Type 2 diabetes, age 40–75 | Benefit generally favours treatment; statins are recommended across guidelines in this group | Strong |
| LDL cholesterol persistently ≥190 mg/dL (often familial) | Treatment recommended regardless of calculated risk; lifetime exposure is what drives harm | Strong |
| No heart disease, estimated 10-year risk ≥10% | At least moderate net benefit (USPSTF, moderate certainty) | Moderate |
| No heart disease, borderline/intermediate risk | Genuinely a judgement call; coronary calcium scoring or Lp(a) can break the tie | Moderate to limited |
| Woman under 40, no risk factors, isolated mildly raised LDL | Little trial evidence; guidelines emphasise lifestyle and repeat assessment over medication | Limited |
| Age 76+, starting a statin for the first time | Evidence insufficient to judge net benefit; continuing an existing statin is a separate question | Insufficient |
| Pregnant, breastfeeding, or actively trying to conceive | Statins are generally stopped; FDA advises most pregnant patients discontinue, with rare high-risk exceptions | Cautionary consensus |
Do statins really cause muscle pain?
This is where the evidence is unusually reassuring, and where most public discussion is out of date. Muscle aching is by far the commonest reason women stop a statin — and blinded trials show most of that aching is not caused by the drug.
The CTT collaboration pooled individual participant data from 23 blinded trials — 19 comparing a statin against placebo and four comparing more against less intensive therapy, about 155,000 participants in total. In the first year, statins produced a 7% relative increase in reports of muscle pain or weakness versus placebo (rate ratio 1.07) — an absolute excess of roughly 11 extra people per 1,000 treated. Put differently, only about one in 15 muscle complaints on a statin was actually attributable to the statin. After the first year, there was no significant difference at all between statin and placebo.
The SAMSON trial tested this individually. Sixty people who had already quit statins because of side effects took, in random order, months of atorvastatin, months of identical placebo, and months of nothing. Average symptom intensity was 16.3 on statin, 15.4 on placebo, and 8.0 on no tablet — a nocebo ratio of 0.90, meaning 90% of the symptom burden was reproduced by a dummy pill. The symptoms were real; the cause largely was not the drug. Notably, half the participants restarted a statin afterwards, once they had seen their own data.
None of this means muscle symptoms should be dismissed. Statins can genuinely cause myopathy — clinically significant muscle injury, conventionally estimated at around 1 case per 10,000 treated people per year. Rhabdomyolysis, the severe muscle breakdown that can damage the kidneys, is rarer still, though published rates vary widely with how strictly cases are defined: roughly 1 to 3 per 100,000 person-years for severe, hospital-confirmed cases, and higher when broader diagnostic coding is used. Whatever the exact figure, the practical point does not change: severe or spreading muscle pain with weakness, or dark cola-coloured urine, is a same-day medical problem, not a wait-and-see one.
What about blood sugar and diabetes?
This effect is real and should not be brushed off. In a 2024 individual-participant analysis of 19 blinded trials (123,940 participants, median 4.3 years), low- or moderate-intensity statin therapy raised new diabetes diagnoses by about 10%, and high-intensity therapy by about 36%. The crucial context: the average rise in blood sugar was small, and roughly 62% of new diagnoses occurred in people whose baseline glycaemia was already in the top quarter — close enough to the diagnostic line that a small nudge crossed it. For someone with existing cardiovascular risk, the events prevented generally outweigh the diagnoses added; for a woman at low cardiac risk with prediabetes, the calculus is closer, and worth naming out loud with your clinician. Context on the numbers in blood sugar levels by age.
Statins and pregnancy
Statins are generally stopped before and during pregnancy and while breastfeeding — a decision made with the prescriber rather than unilaterally, since what happens next depends on why the statin was started. In 2021 the FDA removed the blanket contraindication — not because statins became safe in pregnancy, but because an absolute ban blocked care for a very small group at extreme risk, such as women with homozygous familial hypercholesterolaemia or established heart disease. The FDA's own guidance still states that most pregnant patients should stop, and that patients should not breastfeed while taking a statin, because the drug can pass into breast milk. Practically: if you could become pregnant, this belongs in the first conversation, alongside contraception, not the one after a positive test.
Interactions worth flagging
Some statins are broken down by the CYP3A4 enzyme, so blood levels can rise when combined with certain macrolide antibiotics (such as clarithromycin), some antifungals, particular HIV and hepatitis C antivirals, amiodarone, ciclosporin, and gemfibrozil. Large quantities of grapefruit juice matter for some statins and not others. Pharmacists are excellent at this — bring your full list, including supplements, and let them check rather than guessing from a leaflet.
What if the risk estimate is borderline?
Two tests can move an uncertain decision. A coronary calcium score looks directly at whether calcified plaque is present; the 2026 guideline supports selective use in women aged 45 and over at borderline or intermediate risk, and a score of zero can reasonably support waiting. One caveat is specific to women: coronary arteries calcify later in women than in men, so a zero score means less in a woman in her forties than in a man of the same age — the scan detects calcified plaque only, and soft, non-calcified plaque is invisible to it. Lipoprotein(a) is largely genetic and should be measured at least once in adulthood — ≥125 nmol/L (or ≥50 mg/dL) is associated with about 1.4-fold higher long-term risk, and ≥250 nmol/L with at least double. ApoB counts atherogenic particles directly and can reveal residual risk when LDL looks normal, though it has not replaced LDL cholesterol as the primary treatment target in guidelines. And whatever is decided about medication, the diet and activity evidence stands on its own — see how to lower cholesterol.
All lab values here are reference ranges, not diagnoses. Methods and cutoffs vary between laboratories, and a single reading is a snapshot — decisions should rest on repeated measurements interpreted alongside your full history.
When to see a doctor
Call 911 or go to an emergency department now if you have chest pressure, pain or discomfort; pain spreading to the jaw, neck, back or arm; sudden shortness of breath; or sudden severe weakness, drooping, confusion or trouble speaking. Women's heart attacks more often present without crushing chest pain — see heart attack symptoms in women. Do not drive yourself.
Seek urgent, same-day care for severe or widespread muscle pain with weakness, dark or cola-coloured urine, yellowing of the eyes or skin, or unusual bruising while taking a statin.
Book a routine appointment to review your cholesterol if you have a family history of early heart disease, early menopause or premature ovarian insufficiency, a history of preeclampsia or gestational diabetes, an autoimmune condition, or you are simply unsure whether your risk was ever formally calculated. If you have stopped a statin because of side effects, that is worth revisiting rather than filing away — rechallenge, a different statin, or a different approach entirely are all standard options a prescriber can weigh. Explore more in heart health.
